Clinical trial
Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell…
NCT00006488 · National Center for Research Resources (NCRR), NIH · Completed
Key facts
| NCT number | NCT00006488 |
|---|---|
| Title | Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease |
| Lead sponsor | National Center for Research Resources (NCRR), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Drug |
| Interventions | recombinant-methionyl human glial cell line-derived neurotrophic factor |
| First posted | Nov 9, 2000 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: